No issues with clinical efficacy or safety were identified in the CRL No additional clinical data or trials have been requested Mumbai, India, July 13, 2023 – Sun Pharma Advanced Research Company Ltd. (Reuters: SPRC.BO, Bloomberg: SPADV IN,…Original Article
FDA Issues Complete Response Letter for PDP-716 NDA Due to Inspection Findings at Third-Party API Manufacturing Facility
